Tests remote ischemic conditioning for sleep problems in Parkinson's disease
Tests a cuff-based treatment for poor sleep in people with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Remote Ischemic Conditioning for Sleep Disturbances and Other Non-motor Symptoms in Parkinson's Disease
Key facts
- Where
- Nanjing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 to 70 with Parkinson's disease and insomnia. They will have a cuff placed on the arm for 7 days, either at high or low pressure.
- Age
- 50 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Parkinson's disease for 5 years or less, Hoehn and Yahr stage I-III in the "on" state, with insomnia and clinically significant sleep complaints (for example PDSS-2 total score ≥ 18 points).
- Earlier treatment
- A stable regimen of antiparkinsonian medications for at least 4 weeks before enrollment, with no dose changes expected during the study.
Main reasons for not taking part
- Insomnia caused by other severe medical conditions
- Psychotic symptoms or severe anxiety or depression
- Other sleep disorders that need specific treatment, such as moderate-to-severe sleep apnea or restless legs syndrome
- Significant cerebrovascular disease, brain tumor, brain infection or other neurological disorders that may affect sleep or study tests
- Conditions that make the cuff treatment, MRI or EEG unsafe
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 70 years old?
Source: NCT07299240, who can take part
Where in China
- The Affiliated Brain Hospital of Nanjing Medical University, 264 Guangzhou RoadNanjing, ChinaContact: Haochen Sun, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Jiangsu Province Nanjing Brain Hospital
- Trial code
- NCT07299240
- Record updated
- 28 July 2026
- Original description
This single-center, randomized, single-blind, sham-controlled clinical trial aims to evaluate whether remote ischemic conditioning (RIC) can improve sleep disturbances and other non-motor symptoms in patients with Parkinson's disease (PD). Forty-eight PD patients with insomnia will be randomly assigned in a 1:1 ratio to receive either active RIC (cuff inflation to high pressure) or sham RIC (cuff inflation to low pressure) for 7 consecutive days, in addition to their standard antiparkinsonian medications. Subjective sleep scales, sleep diaries, validated rating scales for motor and non-motor symptoms, and overnight polysomnography will be used to assess treatment effects at baseline, after the 7-day intervention, and during short-term follow-up. The study will also explore potential mechanisms of RIC by combining EEG, functional MRI, retinal optical coherence tomography, and blood biomarkers.Read full original descriptionShow less
Remote Ischemic Conditioning for Sleep Disturbances and Other Non-motor Symptoms in Parkinson's Disease: a Randomized, Single-blind, Sham-controlled Clinical Study
This single-center, randomized, single-blind, sham-controlled clinical trial aims to evaluate whether remote ischemic conditioning (RIC) can improve sleep disturbances and other non-motor symptoms in patients with Parkinson's disease (PD). Forty-eight PD patients with insomnia will be randomly assigned in a 1:1 ratio to receive either active RIC (cuff inflation to high pressure) or sham RIC (cuff inflation to low pressure) for 7 consecutive days, in addition to their standard antiparkinsonian medications. Subjective sleep scales, sleep diaries, validated rating scales for motor and non-motor symptoms, and overnight polysomnography will be used to assess treatment effects at baseline, after the 7-day intervention, and during short-term follow-up. The study will also explore potential mechanisms of RIC by combining EEG, functional MRI, retinal optical coherence tomography, and blood biomarkers.
Inclusion: Diagnosis of Parkinson's disease according to the Movement Disorder Society (MDS) clinical diagnostic criteria; Age between 50 and 70 years; Disease duration ≤ 5 years; Hoehn and Yahr stage I-III in the "on" state; Presence of insomnia that meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria and clinically significant sleep complaints (for example, Parkinson's Disease Sleep Scale-2 [PDSS-2] total score ≥ 18 points); On a stable regimen of antiparkinsonian medications for at least 4 weeks prior to enrollment, with no expected dose changes during the study period; Able to understand the study procedures and provide written informed consent (or consent provided by a legally authorized representative when appropriate).
Exclusion: Contraindications to MRI or EEG examinations (e.g., pacemaker, severe claustrophobia, metallic implants incompatible with MRI); Secondary insomnia due to other severe medical conditions (e.g., uncontrolled cardiopulmonary, hepatic, renal, or endocrine diseases); Other primary sleep disorders such as moderate-to-severe obstructive sleep apnea, restless legs syndrome, periodic limb movement disorder, or rapid eye movement sleep behavior disorder that require specific treatment; History of significant cerebrovascular disease, brain tumor, central nervous system infection, or other neurological disorders that may interfere with sleep or study assessments; Contraindications to remote ischemic conditioning (RIC), including severe peripheral arterial disease of the upper limbs, local soft tissue infection or damage at the cuff site, subclavian artery thrombosis, malignant hypertension, severe cardiac disease, active bleeding disorders, or other conditions judged unsafe by the investigator; Current psychotic symptoms or severe anxiety or depression (e.g., Hamilton Anxiety Scale score ≥ 14 or Hamilton Depression Scale score ≥ 17); Participation in another interventional clinical trial within the past 3 months; Inability to comply with the study procedures or follow-up visits, as judged by the investigator.